Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?

On the EMBARK trial (Freedland et al., PMID 37851874), 25% of men had a prostatectomy and the publication states, "Patients were excluded … if after radical prostatectomy they were considered by the investigator to be a candidate for salvage radiation therapy." Why was salvage radiation therapy excluded?

2 Answers

Mednet MemberInvited Expert

Radiation Oncology

Answered on

Although there have been other efforts to profile the role of enzalutamide (e.g., SALV-ENZA, Tran et al., PMID 36367998) or other second generation androgen axis inhibitors (e.g., FORMULA-509) in conjunction with salvage RT, EMBARK (Freedland et al., PMID 38320501) was designed to test the efficacy ...

Join for free or sign in to see the full answer

Mednet Member

Radiation Oncology · Lafayette Radiation Center

Answered on

I’ve asked this question to people on the EMBARK trial as well as reps and presenters, since it came out.

I very rarely use EMBARK. The main problem was the lack of PET. The study quoted above for the "EMBARK-like" cohort at UCLA supports my practice pattern.

I will, however, discuss EMBARK with pati...

Join for free or sign in to see the full answer